Diagnostic and Prognostic Value of New Quick Tests of Action Slowing in Stroke and in Cognitive Neurodegenerative Disease
NCT ID: NCT05785156
Last Updated: 2023-03-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
129 participants
OBSERVATIONAL
2021-07-16
2025-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predictive Value for Stroke
NCT00451529
Study of Factors Influencing Post-stroke Dementia
NCT01330160
Diffusion Spectroscopy in Stroke
NCT02833961
Assessing Accuracy of Clinical Diagnosis and Lesion Location in Acute Neurological Deficits - How Good Are Neurologists?
NCT03009656
Diagnostic and Prognostic Role of Clot Analysis in Stroke Patients
NCT05760326
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
acute stroke patients
quick tests
New quick tests are
* Batterie MindPlus (Brevet n° FR1908081, Suarez 2019) is a quick reaction time battery and
* Minimal Cognitive Evaluation (MCE) test (Sardi et al, 2019) is a cognitive screening tests including a specific assessment of slowing
cognitive neurodegenerative disorders
cognitive neurodegenerative disorders (Alzheimer Disease (AD), Lewy Body disease (LBD), FrontoTemporal lobar degeneration (FTLD), Cortico Basal Degeneration (CBD) and Progressive Supra Nuclear Palsy (PSNP)
quick tests
New quick tests are
* Batterie MindPlus (Brevet n° FR1908081, Suarez 2019) is a quick reaction time battery and
* Minimal Cognitive Evaluation (MCE) test (Sardi et al, 2019) is a cognitive screening tests including a specific assessment of slowing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
quick tests
New quick tests are
* Batterie MindPlus (Brevet n° FR1908081, Suarez 2019) is a quick reaction time battery and
* Minimal Cognitive Evaluation (MCE) test (Sardi et al, 2019) is a cognitive screening tests including a specific assessment of slowing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* French native language,
* Social Security affiliation.
* University Memory Clinic for: Mild severity disorder (MMSE\> 19) or major severity disorder related to AD : Albert 2011 criteria ; McKhann 2011
* to MCL according to McKeith criteria
* to FTLD according to Rascovsky 2011 criteria
* BBD according to Armstrong's criteria
* related to PSP according to Höglinger criteria
Exclusion Criteria
* Previously diagnosed dementia
* Other current or past brain condition
* severe head trauma
* epilepsy prior to stroke still requiring previous treatment
* Parkinson disease, multiple sclerosis...
* brain tumor or brain radiation therapy
* Current or past schizophrenia or psychosis
* Active or past psychiatric disorders requiring a stay\> 2 days in a specialized environment
* Contra indication to MRI
* Comorbidity with life expectancy \<1 year
* Comorbidity affecting cognition in particular:
* Alcohol (\> 3 glasses / day) or history of alcohol withdrawal syndrome
* opiate or cocaine addiction or opiate withdrawal syndrome
* renal failure (dialysis or creatinine clearance \<30)
* hepatic failure (spontaneous INR\> 1.5 or PT \<60%)
* respiratory failure requiring oxygen therapy
* heart failure (orthopnea\> 2 pillows)
* persistent vigilance disturbances (NIHSS1a score ≤1)
* cancer with paraneoplastic syndrome
* treatment with gold salts, D Penicillamine or other treatment with cognitive effect
* Patient under guardianship or curators or private under public law
* Pregnant and / or lactating wom
40 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire, Amiens
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Amiens
Amiens, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PI2021_843_0082
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.